Isogenica Ltd today announced that it has executed a services agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ("J&JPRD").
Isogenica licensed its CIS display technology to J&JPRD (as successor in business to Centocor Research & Development, Inc.) in 2008 for application with the J&JPRD's Centyrin scaffold protein platform. This latest services agreement allows Isogenica to perform discovery work with the platform.
Isogenica's CEO, Dr Kevin Matthews, said: "We are delighted to partner on this opportunity. We have been working hard to make CIS display an 'industrialised' molecular biology tool and it is great to see the progress we have made rewarded with this latest collaboration."
Neurological Narratives: A Journey into Women's Brain Health Research